Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings.
Marta Camici, Eva Piano Mortari, Giulia Del Duca et al.
✦ AI-curated · Sources linked
Case in brief
A previously healthy 39-year-old man developed long COVID with cognitive dysfunction, disabling fatigue, and autonomic symptoms despite multiple multidisciplinary interventions. Testing showed markedly elevated autoantibodies against G protein-coupled receptors, an inverted CD4:CD8 T-cell ratio, CD8 T-cell–monocyte complexes, and spontaneous IFNγ release. During high-dose intravenous immunoglobulin treatment, alongside cognitive stimulation, fatigue scores normalised, neurocognitive performance returned to normal, and quality of life improved; he fully recovered within 1 year. Treatment was accompanied by reductions in the cellular complexes, spontaneous IFNγ and TNF production, endothelial inflammation markers, and autoantibody titres.
What made this case unusual
The report links clinical recovery during immunoglobulin treatment with a reduction in CD8 T-cell–monocyte complexes and other immune abnormalities, including spontaneous cytokine production. The authors propose these cellular interactions as a possible feature of post-viral immune dysregulation, while acknowledging that a single case cannot establish causality.
Diagnostic / clinical pearl
In a patient with persistent multisystem long COVID, immune profiling may reveal abnormalities such as elevated G protein-coupled receptor autoantibodies and CD8 T-cell–monocyte complexes; changes during treatment are hypothesis-generating, not proof of mechanism or efficacy.